short2312 schreef:
28 mei 2010 - 10:33
Legal name: Pharming Group N.V.
Title: PHARMING SUCCESSFULLY COMPLETES EQUITY FUNDRAISING OF €12 MILLION
Comments: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.. Leiden, The Netherlands, May 28, 2010. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) announces that it has successfully completed an equity fundraising of €12.0 million through a private placement of ordinary shares with new and existing investors (the “Offering”). The Company deems the net proceeds of the Offering sufficient to finalize the regulatory approval process and start of commercialization of Rhucin for the treatment of Hereditary Angioedema, if the marketing authorisation by the European Union is granted. In the context of the Offering, a total of 100,000,000 million new shares (the "Offer Shares") have been offered for an issue price of €0.12 per Offer Share. The Offering was launched this morning and the order book for the Offering was closed today . Payment for and delivery of the Offer Shares is expected to take place 3 business days after today, at which date the Offer Shares are expected to be admitted to trading and listing of Euronext Amsterdam by NYSE Euronext. As a result of the Offering and a number of anti-dilution events triggered by the Offering, Pharming’s total number of outstanding ordinary shares will increase to 272,447,697.